W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Promoted life sciences community and communicated economic and health benefits of the industry. P.L. 112-144, The Food and Drug Administration Safety and Innovation Act of 2012 as it relates to reform of the drug and device approval process and legislative initiatives as well as tracking of FDA performance data, and provisions providing incentives for development of new antibiotics (H.R. 2182: GAIN ACT).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Budget/Appropriations BUD
H.J.Res. 117: Continuing Appropriations Resolution for Fiscal Year 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Taxation/Internal Revenue Code TAX
H.R. 436: Health Care Cost Reduction Act of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.